Terms: = Ovarian cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR
250 results:
1. Mesothelin-based car-T cells exhibit potent antitumor activity against ovarian cancer.
Guo J; Zeng X; Zhu Y; Yang D; Zhao X
J Transl Med; 2024 Apr; 22(1):367. PubMed ID: 38637885
[TBL] [Abstract] [Full Text] [Related]
2. Armored TGFβRIIDN ROR1-car T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1.
Tran TM; Chand Thakuri BK; Nurmukhambetova S; Lee JJ; Hu P; Tran NQ; Steimle B; Dash P; Schneider D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38609317
[TBL] [Abstract] [Full Text] [Related]
3. Efficient car T cell targeting of the CA125 extracellular repeat domain of MUC16.
Casey NP; Kleinmanns K; Forcados C; Gelebart PF; Joaquina S; Lode M; Benard E; Kaveh F; Caulier B; Helgestad Gjerde C; García de Jalón E; Warren DJ; Lindemann K; Rokkones E; Davidson B; Myhre MR; Kvalheim G; Bjørge L; McCormack E; Inderberg EM; Wälchli S
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604812
[TBL] [Abstract] [Full Text] [Related]
4. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for ovarian cancer.
Li J; Hu H; Lian H; Yang S; Liu M; He J; Cao B; Chen D; Hu Y; Zhi C; Shen Y; Ye X; He B; Zhao M; Fan W; Xu L; Leidner R; Wu Q; Yang L; Zhang Z
Int J Biol Sci; 2024; 20(5):1578-1601. PubMed ID: 38481806
[No Abstract] [Full Text] [Related]
5. Decoding the mechanisms of chimeric antigen receptor (car) T cell-mediated killing of tumors: insights from granzyme and Fas inhibition.
Montalvo MJ; Bandey IN; Rezvan A; Wu KL; Saeedi A; Kulkarni R; Li Y; An X; Sefat KMSR; Varadarajan N
Cell Death Dis; 2024 Feb; 15(2):109. PubMed ID: 38307835
[TBL] [Abstract] [Full Text] [Related]
6. Folate Receptor Alpha-A Novel Approach to cancer Therapy.
Gonzalez T; Muminovic M; Nano O; Vulfovich M
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256120
[TBL] [Abstract] [Full Text] [Related]
7. Immunotherapy for ovarian cancer: Disappointing or Promising?
Deng M; Tang F; Chang X; Liu P; Ji X; Hao M; Wang Y; Yang R; Ma Q; Zhang Y; Miao J
Mol Pharm; 2024 Feb; 21(2):454-466. PubMed ID: 38232985
[TBL] [Abstract] [Full Text] [Related]
8. Tumor resistance to anti-mesothelin car-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope.
Liu XF; Onda M; Schlomer J; Bassel L; Kozlov S; Tai CH; Zhou Q; Liu W; Tsao HE; Hassan R; Ho M; Pastan I
Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2317283121. PubMed ID: 38227666
[TBL] [Abstract] [Full Text] [Related]
9. car-T cell immunotherapy for ovarian cancer: hushing the silent killer.
Nasiri F; Farrokhi K; Safarzadeh Kozani P; Mahboubi Kancha M; Dashti Shokoohi S; Safarzadeh Kozani P
Front Immunol; 2023; 14():1302307. PubMed ID: 38146364
[TBL] [Abstract] [Full Text] [Related]
10. [Killing effect of anti-MSLN-icar-NK cells derived from induced pluripotent stem cells on ovarian epithelial cancer cells].
Fan RJ; Zhang YF; Wang YY; Wang Y; Zheng W
Zhonghua Fu Chan Ke Za Zhi; 2023 Dec; 58(12):922-929. PubMed ID: 38123198
[No Abstract] [Full Text] [Related]
11. Pyroptosis and the tumor immune microenvironment: A new battlefield in ovarian cancer treatment.
Wang A; Wang Y; Du C; Yang H; Wang Z; Jin C; Hamblin MR
Biochim Biophys Acta Rev Cancer; 2024 Mar; 1879(2):189058. PubMed ID: 38113952
[TBL] [Abstract] [Full Text] [Related]
12. Hyperactive Rac stimulates cannibalism of living target cells and enhances car-M-mediated cancer cell killing.
Mishra AK; Rodriguez M; Torres AY; Smith M; Rodriguez A; Bond A; Morrissey MA; Montell DJ
Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2310221120. PubMed ID: 38109551
[TBL] [Abstract] [Full Text] [Related]
13. Hypoxic 3D Tumor Model for Evaluating of car-T Cell Therapy In Vitro.
Oh JM; Shen K
Methods Mol Biol; 2024; 2748():119-134. PubMed ID: 38070112
[TBL] [Abstract] [Full Text] [Related]
14. CD44v6 specific car-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma.
Ciulean IS; Fischer J; Quaiser A; Bach C; Abken H; Tretbar US; Fricke S; Koehl U; Schmiedel D; Grunwald T
Front Immunol; 2023; 14():1290488. PubMed ID: 38022580
[TBL] [Abstract] [Full Text] [Related]
15. Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and car/IL-15 engineering.
Lee D; Dunn ZS; Guo W; Rosenthal CJ; Penn NE; Yu Y; Zhou K; Li Z; Ma F; Li M; Song TC; Cen X; Li YR; Zhou JJ; Pellegrini M; Wang P; Yang L
Nat Commun; 2023 Nov; 14(1):6942. PubMed ID: 37938576
[TBL] [Abstract] [Full Text] [Related]
16. Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer.
Wang Y; Han J; Wang D; Cai M; Xu Y; Hu Y; Chen H; He W; Zhang J
Signal Transduct Target Ther; 2023 Oct; 8(1):399. PubMed ID: 37857598
[TBL] [Abstract] [Full Text] [Related]
17. Characterizing the regulatory Fas (CD95) epitope critical for agonist antibody targeting and car-T bystander function in ovarian cancer.
Mondal T; Gaur H; Wamba BEN; Michalak AG; Stout C; Watson MR; Aleixo SL; Singh A; Condello S; Faller R; Leiserowitz GS; Bhatnagar S; Tushir-Singh J
Cell Death Differ; 2023 Nov; 30(11):2408-2431. PubMed ID: 37838774
[TBL] [Abstract] [Full Text] [Related]
18. Engineering strategies to optimise adoptive cell therapy in ovarian cancer.
Guerra C; Kalaitsidou M; Kueberuwa G; Hawkins R; Edmondson R
Cancer Treat Rev; 2023 Dec; 121():102632. PubMed ID: 37837788
[TBL] [Abstract] [Full Text] [Related]
19. Novel mesothelin-targeted chimeric antigen receptor-modified UNKT cells are highly effective in inhibiting tumor progression.
Jiang W; Gu G; Zhang Y; Song Y; Shi M; Wang G; Li H; Tao T; Qin J; Li X; Jia H; Jiao F; Xu W; Huang X
Pharmacol Res; 2023 Nov; 197():106942. PubMed ID: 37775021
[TBL] [Abstract] [Full Text] [Related]
20. Nanoscale car Organization at the Immune Synapse Correlates with car-T Effector Functions.
Sajman J; Yakovian O; Unger Deshet N; Almog S; Horn G; Waks T; Globerson Levin A; Sherman E
Cells; 2023 Sep; 12(18):. PubMed ID: 37759484
[TBL] [Abstract] [Full Text] [Related]
[Next]